A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.
OBJECTIVE: To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. METHODS: We reviewed CV outcomes during the long-term followup of patients in th...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826272554345562112 |
|---|---|
| author | Suppiah, R Judge, A Batra, R Flossmann, O Harper, L Höglund, P Javaid, M Jayne, D Mukhtyar, C Westman, K Davis, J Hoffman, G McCune, W Merkel, P St Clair, E Seo, P Spiera, R Stone, J Luqmani, R |
| author_facet | Suppiah, R Judge, A Batra, R Flossmann, O Harper, L Höglund, P Javaid, M Jayne, D Mukhtyar, C Westman, K Davis, J Hoffman, G McCune, W Merkel, P St Clair, E Seo, P Spiera, R Stone, J Luqmani, R |
| author_sort | Suppiah, R |
| collection | OXFORD |
| description | OBJECTIVE: To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. METHODS: We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict the absolute risk of a CV event. The model was tested using the Wegener's Granulomatosis Etanercept Trial (WGET) cohort. RESULTS: Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33 (11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11-1.90), diastolic hypertension (OR 1.97, 95% CI 0.98-3.95), and positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20-0.74). The model was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80). CONCLUSION: Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to myeloperoxidase ANCA or negative ANCA status. |
| first_indexed | 2024-03-06T22:14:23Z |
| format | Journal article |
| id | oxford-uuid:52e781d3-5d33-44e9-b24c-3910f7d68fbe |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:14:23Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:52e781d3-5d33-44e9-b24c-3910f7d68fbe2022-03-26T16:28:23ZA model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:52e781d3-5d33-44e9-b24c-3910f7d68fbeEnglishSymplectic Elements at Oxford2011Suppiah, RJudge, ABatra, RFlossmann, OHarper, LHöglund, PJavaid, MJayne, DMukhtyar, CWestman, KDavis, JHoffman, GMcCune, WMerkel, PSt Clair, ESeo, PSpiera, RStone, JLuqmani, ROBJECTIVE: To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. METHODS: We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict the absolute risk of a CV event. The model was tested using the Wegener's Granulomatosis Etanercept Trial (WGET) cohort. RESULTS: Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33 (11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11-1.90), diastolic hypertension (OR 1.97, 95% CI 0.98-3.95), and positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20-0.74). The model was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80). CONCLUSION: Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to myeloperoxidase ANCA or negative ANCA status. |
| spellingShingle | Suppiah, R Judge, A Batra, R Flossmann, O Harper, L Höglund, P Javaid, M Jayne, D Mukhtyar, C Westman, K Davis, J Hoffman, G McCune, W Merkel, P St Clair, E Seo, P Spiera, R Stone, J Luqmani, R A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. |
| title | A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. |
| title_full | A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. |
| title_fullStr | A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. |
| title_full_unstemmed | A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. |
| title_short | A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. |
| title_sort | model to predict cardiovascular events in patients with newly diagnosed wegener s granulomatosis and microscopic polyangiitis |
| work_keys_str_mv | AT suppiahr amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT judgea amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT batrar amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT flossmanno amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT harperl amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT hoglundp amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT javaidm amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT jayned amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT mukhtyarc amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT westmank amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT davisj amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT hoffmang amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT mccunew amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT merkelp amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT stclaire amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT seop amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT spierar amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT stonej amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT luqmanir amodeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT suppiahr modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT judgea modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT batrar modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT flossmanno modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT harperl modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT hoglundp modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT javaidm modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT jayned modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT mukhtyarc modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT westmank modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT davisj modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT hoffmang modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT mccunew modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT merkelp modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT stclaire modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT seop modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT spierar modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT stonej modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis AT luqmanir modeltopredictcardiovasculareventsinpatientswithnewlydiagnosedwegenersgranulomatosisandmicroscopicpolyangiitis |